Gilead Sciences’s most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $65.00 short put and a strike $60.00 long put offers a potential 17.1% return on risk over the next 38 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $65.00 by expiration. The full premium credit of $0.73 would be kept by the premium seller. The risk of $4.27 would be incurred if the stock dropped below the $60.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is at 45.67 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Bristol-Myers Files in Japan for New Hepatitis C Drug
Wed, 13 Nov 2013 21:02:19 GMT
Motley Fool – Bristol’s choice to focus its hepatitis C program on Japan first comes as the country opens its door to drug development. That gives Bristol a potential first-to-market edge over Gilead Sciences and Johnson …
Pharmacyclics Drug Wins One Approval, Awaits Another
Wed, 13 Nov 2013 19:15:00 GMT
Investor’s Business Daily – Pharmacyclics Drug Wins One Approval, Awaits Another
J&J-Pharmacyclics Breakthrough Drug Wins U.S. Approval
Wed, 13 Nov 2013 17:33:15 GMT
Bloomberg – Johnson & Johnson and Pharmacyclics Inc. won U.S. approval for their breakthrough therapy to treat a rare blood cancer, becoming the second drug to gain marketing clearance under the process created to …
Gilead Financial Projection And Stock Valuation, Part 2
Wed, 13 Nov 2013 15:15:37 GMT
Seeking Alpha – In Part 1 of our recent Gilead ( GILD ) reports, we laid out a five-year projection for the revenues from Gilead’s existing drugs and new drugs approved since 2011.
Bristol-Myers Squibb’s Radical Transformation
Wed, 13 Nov 2013 01:02:08 GMT
Motley Fool – Bristol-Myers is pulling out of drug discovery in three massive patient population markets. What should investors think of the move?
Also on Market Tamer…
Follow Us on Facebook